Related Experiment Video
Updated: Jun 5, 2026
11:18
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
12.2K
Outcome of T-Lymphoblastic Leukemia-Lymphoma with Hyper C-VAD Regimen
Nasrin Namdari1, Elahe Ataei2, Fatame Ghanbarian2
1Department of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran.
Summary
The Hyper-CVAD chemotherapy regimen shows poor outcomes for T-cell lymphoblastic leukemia (T-ALL) and lymphoma (T-LBL). Allogeneic stem cell transplant significantly improves survival for these aggressive blood cancers.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- T-cell lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are aggressive hematologic malignancies.
- These diseases are associated with poor prognoses in adult patients.
Purpose of the Study:
- To evaluate the efficacy of the Hyper-CVAD chemotherapy protocol in adult patients with T-ALL and T-LBL.
- To assess overall survival (OS) and progression-free survival (PFS) in this patient cohort.
Main Methods:
- Retrospective analysis of 46 adult patients with T-ALL (32 cases) and T-LBL (14 cases) treated with Hyper-CVAD.
- Evaluation of overall survival and progression-free survival rates.
Main Results:
- Two- and 3-year OS rates were 41.8% and 27.8%, respectively.
- Two- and 3-year PFS rates were 36.9% and 25.3%, respectively.
- Allogeneic stem cell transplant (SCT) was the only significant factor associated with improved PFS and OS, with 2-year OS of 80% for SCT recipients versus 20% for non-recipients (p<0.001).
Conclusions:
- The Hyper-CVAD regimen appears inadequate for treating T-ALL and T-LBL.
- Novel targeted agents are needed for induction therapy.
- Allogeneic SCT should be considered as a consolidation strategy for these patients.
